Antisense oligonucleotide: A promising therapeutic option to beat <scp>COVID</scp>‐19
Anaïs M. Quéméner, Marie‐Dominique Galibert
Abstract
The COVID-19 crisis and the development of the first approved mRNA vaccine have highlighted the power of RNA-based therapeutic strategies for the development of new medicines. Aside from RNA-vaccines, antisense oligonucleotides (ASOs) represent a new and very promising class of RNA-targeted therapy. Few drugs have already received approval from the Food and Drug Administration. Here, we underscored why and how ASOs hold the potential to change the therapeutic landscape to beat SARS-CoV-2 viral infections. This article is categorized under: RNA Interactions with Proteins and Other Molecules > Small Molecule-RNA Interactions.
Topics & Concepts
RNAOligonucleotideCoronavirus disease 2019 (COVID-19)Food and drug administrationAntisense RNAVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Messenger RNAComputational biologyBiologyMedicinePharmacologyGeneGeneticsInfectious disease (medical specialty)DiseasePathologyRNA Interference and Gene DeliveryViral Infections and Immunology ResearchRNA and protein synthesis mechanisms